Dr. Reddy's 3QFY01: The Cheminor muscle - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Dr. Reddy's 3QFY01: The Cheminor muscle

Jan 31, 2001

Dr. Reddy’s has reported a 45% growth in net profits, in the third quarter of the current year on the back of a 77% topline growth. However, these numbers are not comparable as the current year’s third quarter numbers include those of Cheminor Laboratories. Infact, on a consolidated basis the company’s topline has grown by 26% plus while the net profit’s have grown by 14% plus. The margin growth has been relatively slower primarily because of the increase of the contribution from bulk drugs. (Bulk drugs contribute around 51% of the combined company’s turnover.)

(Rs m) 3QFY00 3QFY01 Change
Sales 1,210 2,144 77.2%
Other Income 3 84 2706.7%
Expenditure 908 1,687 85.9%
Operating Profit (EBDIT) 303 457 50.9%
Operating Profit Margin (%) 25.0% 21.3%  
Interest 30 76  
Depreciation 44 102 130.5%
Profit before Tax 231 362 57.0%
Other Adjustments   -  
Tax 10 43 326.0%
Profit after Tax/(Loss) 221 320 44.8%
Net profit margin (%) 18.2% 14.9%  
Earnings per share* 27.96 40.47  

While the bulk actives business grew by 27% the generic sales in developed market took off in the third quarter of December 31, 2000. The finished dosages at Rs. 998 m contributed to 46% of revenues. Another significant development in the third quarter was the fact that the company’s anti-cancer compound DRF 1042 entered Phase I of clinical trials.

During the quarter all the company’s main brands Omez (anti–ulcer), Nise (anti–pain), Enam (cardiovascular) and Stamlo registered growth rates much higher than the rate of growth of overall pharmaceutical formulations. While the industry grew by 11%, Omez grew by 20%. Nise registered a growth of 17%, while Enam and Stamlo (including Stamlo Beta) grew by 29% and 26% respectively. The company also launched eight new brands, which catered to therapeutic areas such as anti–arthritis, anti–diabetes and cholesterol reducers.

The stock quotes at Rs 1,300 currently which implies an earnings multiple of 32 times 3QFY01 earnings.

Equitymaster requests your view! Post a comment on "Dr. Reddy's 3QFY01: The Cheminor muscle". Click here!


More Views on News

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

Can the Nifty Fall to 10,200? (Fast Profits Daily)

Sep 24, 2020

The Nifty has reached an important support level today. If it breaks then we could see further downside.


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 25, 2020 (Close)


  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks